Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2021 12:46 ET | Source: Global Blood Therapeutics, Inc.

Europäische Arzneimittelagentur genehmigt GBTs Antrag auf Marktzulassung für Oxbryta® (Voxelotor) zur Behandlung hämolytischer Anämie bei Sichelzellkrankheit

SOUTH SAN FRANCISCO, Kalifornien, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) hat heute bekanntgegeben, dass die Europäische Arzneimittelagentur (EMA) die...
January 27, 2021 12:46 ET | Source: Global Blood Therapeutics, Inc.

L'Agence européenne des médicaments accepte la demande d'autorisation de mise sur le marché de GBT pour Oxbryta® (voxelotor) pour le traitement de l'anémie hémolytique dans la drépanocytose

SOUTH SAN FRANCISCO, Californie, 27 janv. 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd'hui que l'Agence européenne des médicaments (EMA) avait...
January 27, 2021 07:00 ET | Source: Global Blood Therapeutics, Inc.

European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the...
January 07, 2021 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2021, the compensation committee of GBT’s board...
January 05, 2021 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual presentation at the 39th...
December 15, 2020 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on December 1, 2020, the compensation committee of GBT’s board...
December 07, 2020 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Appoints Kim Smith-Whitley, M.D., to Lead Research and Development

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD)...
December 06, 2020 10:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition

Final 72-Week Analyses of Phase 3 HOPE Study Demonstrate Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status Real-World Experience Study Results Consistent...
December 06, 2020 10:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601

Two Inclacumab Pivotal Phase 3 Clinical Trials Expected to Begin in First Half of 2021 GBT021601 – Potent Next-Generation Hemoglobin S Polymerization Inhibitor Shown to be Highly Effective in SCD...
December 03, 2020 15:55 ET | Source: Global Blood Therapeutics, Inc.

GBT lance un programme d'accès anticipé pour voxelotor chez les patients atteints de drépanocytose en Europe et dans d'autres régions en dehors des États-Unis

SOUTH SAN FRANCISCO, Californie, 03 déc. 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd'hui le lancement d'un programme d'accès anticipé pour...